159 related articles for article (PubMed ID: 24355074)
1. Molecular analyses of novel ASAH1 mutations causing Farber lipogranulomatosis: analyses of exonic splicing enhancer inactivating mutation.
Bashyam MD; Chaudhary AK; Kiran M; Reddy V; Nagarajaram HA; Dalal A; Bashyam L; Suri D; Gupta A; Gupta N; Kabra M; Puri RD; RamaDevi R; Kapoor S; Danda S
Clin Genet; 2014 Dec; 86(6):530-8. PubMed ID: 24355074
[TBL] [Abstract][Full Text] [Related]
2. Molecular basis of acid ceramidase deficiency in a neonatal form of Farber disease: identification of the first large deletion in ASAH1 gene.
Alves MQ; Le Trionnaire E; Ribeiro I; Carpentier S; Harzer K; Levade T; Ribeiro MG
Mol Genet Metab; 2013 Jul; 109(3):276-81. PubMed ID: 23707712
[TBL] [Abstract][Full Text] [Related]
3. Novel V97G ASAH1 mutation found in Farber disease patients: unique appearance of the disease with an intermediate severity, and marked early involvement of central and peripheral nervous system.
Chedrawi AK; Al-Hassnan ZN; Al-Muhaizea M; Colak D; Al-Younes B; Albakheet A; Tulba S; Kaya N
Brain Dev; 2012 May; 34(5):400-4. PubMed ID: 21893389
[TBL] [Abstract][Full Text] [Related]
4. ASAH1 pathogenic variants associated with acid ceramidase deficiency: Farber disease and spinal muscular atrophy with progressive myoclonic epilepsy.
Elsea SH; Solyom A; Martin K; Harmatz P; Mitchell J; Lampe C; Grant C; Selim L; Mungan NO; Guelbert N; Magnusson B; Sundberg E; Puri R; Kapoor S; Arslan N; DiRocco M; Zaki M; Ozen S; Mahmoud IG; Ehlert K; Hahn A; Gokcay G; Torcoletti M; Ferreira CR
Hum Mutat; 2020 Sep; 41(9):1469-1487. PubMed ID: 32449975
[TBL] [Abstract][Full Text] [Related]
5. Farber disease in a patient from China.
Bao X; Ma M; Zhang Z; Xu Y; Qiu Z
Am J Med Genet A; 2020 Sep; 182(9):2184-2186. PubMed ID: 32706452
[TBL] [Abstract][Full Text] [Related]
6. Atypical presentation of infantile-onset farber disease with novel ASAH1 mutations.
Kim SY; Choi SA; Lee S; Lee JS; Hong CR; Lim BC; Kang HJ; Kim KJ; Park SH; Choi M; Chae JH
Am J Med Genet A; 2016 Nov; 170(11):3023-3027. PubMed ID: 27411168
[TBL] [Abstract][Full Text] [Related]
7. Farber lipogranulomatosis type 1--late presentation and early death in a Croatian boy with a novel homozygous ASAH1 mutation.
Cvitanovic-Sojat L; Gjergja Juraski R; Sabourdy F; Fensom AH; Fumic K; Paschke E; Levade T
Eur J Paediatr Neurol; 2011 Mar; 15(2):171-3. PubMed ID: 20609603
[TBL] [Abstract][Full Text] [Related]
8. rAAV-mediated over-expression of acid ceramidase prevents retinopathy in a mouse model of Farber lipogranulomatosis.
Zhang H; Nagree MS; Liu H; Pan X; Medin JA; Lipinski DM
Gene Ther; 2023 Apr; 30(3-4):297-308. PubMed ID: 35902747
[TBL] [Abstract][Full Text] [Related]
9. ASAH1-related disorders: Description of 15 novel pediatric patients and expansion of the clinical phenotype.
Mahmoud IG; Elmonem MA; Zaki MS; Ramadan A; Al-Menabawy NM; El-Gamal A; Mansour L; Issa MY; Abdel-Hamid MS; Abdel-Hady S; Khalifa I; Ibrahim A; Solyom A; Rolfs A; Selim L
Clin Genet; 2020 Dec; 98(6):598-605. PubMed ID: 32875576
[TBL] [Abstract][Full Text] [Related]
10. Acid ceramidase deficiency associated with spinal muscular atrophy with progressive myoclonic epilepsy.
Gan JJ; Garcia V; Tian J; Tagliati M; Parisi JE; Chung JM; Lewis R; Baloh R; Levade T; Pierson TM
Neuromuscul Disord; 2015 Dec; 25(12):959-63. PubMed ID: 26526000
[TBL] [Abstract][Full Text] [Related]
11. Spinal muscular atrophy and Farber disease due to ASAH1 variants: A case report.
Lee BH; Mongiovi P; Levade T; Marston B; Mountain J; Ciafaloni E
Am J Med Genet A; 2020 Oct; 182(10):2369-2371. PubMed ID: 32627310
[TBL] [Abstract][Full Text] [Related]
12. [A case report of childhood Farber's disease and literature review].
Bao XH; Tian JM; Ji TY; Chang XZ
Zhonghua Er Ke Za Zhi; 2017 Jan; 55(1):54-58. PubMed ID: 28072961
[No Abstract] [Full Text] [Related]
13. Allogeneic hematopoietic cell transplantation in Farber disease.
Ehlert K; Levade T; Di Rocco M; Lanino E; Albert MH; Führer M; Jarisch A; Güngör T; Ayuk F; Vormoor J
J Inherit Metab Dis; 2019 Mar; 42(2):286-294. PubMed ID: 30815900
[TBL] [Abstract][Full Text] [Related]
14. A novel mutation in an atypical presentation of the rare infantile Farber disease.
Al Jasmi F
Brain Dev; 2012 Jun; 34(6):533-5. PubMed ID: 21982811
[TBL] [Abstract][Full Text] [Related]
15. Generation of an induced pluripotent stem cell line (TRNDi030-A) from a patient with Farber disease carrying a homozygous p. Y36C (c. 107 A>G) mutation in ASAH1.
Brooks BM; Yeh CD; Beers J; Liu C; Cheng YS; Gorshkov K; Zou J; Zheng W; Chen CZ
Stem Cell Res; 2021 May; 53():102387. PubMed ID: 34088014
[TBL] [Abstract][Full Text] [Related]
16. Acid Ceramidase Depletion Impairs Neuronal Survival and Induces Morphological Defects in Neurites Associated with Altered Gene Transcription and Sphingolipid Content.
Kyriakou K; Lederer CW; Kleanthous M; Drousiotou A; Malekkou A
Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32111095
[TBL] [Abstract][Full Text] [Related]
17. Farber lipogranulomatosis: clinical and molecular genetic analysis reveals a novel mutation in an Indian family.
Devi ARR; Gopikrishna M; Ratheesh R; Savithri G; Swarnalata G; Bashyam M
J Hum Genet; 2006; 51(9):811-814. PubMed ID: 16951918
[TBL] [Abstract][Full Text] [Related]
18. Acid Ceramidase Deficiency in Mice Leads to Severe Ocular Pathology and Visual Impairment.
Yu FPS; Sajdak BS; Sikora J; Salmon AE; Nagree MS; Gurka J; Kassem IS; Lipinski DM; Carroll J; Medin JA
Am J Pathol; 2019 Feb; 189(2):320-338. PubMed ID: 30472209
[TBL] [Abstract][Full Text] [Related]
19. C26-Ceramide as highly sensitive biomarker for the diagnosis of Farber Disease.
Cozma C; Iurașcu MI; Eichler S; Hovakimyan M; Brandau O; Zielke S; Böttcher T; Giese AK; Lukas J; Rolfs A
Sci Rep; 2017 Jul; 7(1):6149. PubMed ID: 28733637
[TBL] [Abstract][Full Text] [Related]
20. Molecular analysis of acid ceramidase deficiency in patients with Farber disease.
Bär J; Linke T; Ferlinz K; Neumann U; Schuchman EH; Sandhoff K
Hum Mutat; 2001 Mar; 17(3):199-209. PubMed ID: 11241842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
